EPISODIC MIGRAINE

This phase 3 trial is testing atogepant, a daily pill already approved for adults, to prevent episodic migraines in children aged 6 to 17. About 450 participants will receive either a low or high dose of the drug or a placebo for 12 weeks. The goal is to see if it safely reduces …

This study tests whether eptinezumab, given through a vein, can safely reduce the number of migraine days in children and teens aged 6 to 17 with episodic migraine. Participants receive either the drug or a placebo, and researchers track monthly migraine days over 12 weeks. The g…

This study will follow 2,641 people with episodic or chronic migraine to see how well newer drugs—like monoclonal antibodies, gepants, ditans, and a sumatriptan-naproxen combo—work in everyday life. Researchers will track monthly migraine days, pain relief within 2 hours, and any…

This study tests whether atorvastatin, a common cholesterol medicine, can prevent migraine attacks in adults with episodic migraine (4-14 attacks per month). Researchers will compare a 20mg dose, a 40mg dose, and a placebo over several months. The goal is to see if the drug reduc…

This observational study will follow 700 people with migraine who are prescribed anti-CGRP drugs (monoclonal antibodies or gepants) for prevention. Over two years, researchers will track changes in monthly headache days, migraine impact, and disability. The goal is to see how the…

This phase 3 trial tests whether injections of Xeomin (a botulinum toxin type A) into head and neck muscles can prevent episodic migraines. About 990 adults with episodic migraine will receive either Xeomin or a placebo every 12 weeks for up to 55 weeks. The main goal is to see i…

This study looks at the safety and effectiveness of atogepant, a drug already approved for migraine prevention, in Korean adults. About 3000 people with chronic or episodic migraines will take the drug as prescribed by their doctor and be followed for up to 12 weeks. The goal is …

This study tests a new medication called IPN10200, given as injections into the head and neck muscles, to prevent migraines in adults. About 641 people with episodic or chronic migraine will receive either the drug or a placebo. The goal is to see if it safely reduces the number …

This pilot study will test whether chiropractic care can help people with episodic migraine (4-13 migraine days per month). Sixty adults aged 18-65 will receive either personalized chiropractic care or headache health education. The main goal is to see if a larger trial is feasib…

This study tests whether numbing certain scalp nerves can stop migraine pain quickly and prevent future attacks. Researchers will compare blocking two nerves versus ten nerves in 60 people who have frequent migraines. The goal is to see if this approach can eliminate headache pai…

This study tests whether Gou-Teng-San (GTS), a traditional herbal medicine, can help adults with episodic migraine. About 40 participants will be randomly assigned to receive GTS or a placebo. Researchers will measure if GTS reduces the number of migraine days per month and eases…